Thrombo-embolic venous diseases are represented by deep venous thrombosis and/or pulmonary embolism. In some patients with repeated thrombosis or occurrence of thrombosis in unusual sites, the etiological workup remains negative, which represents a problem for the management of the anticoagulant treatments. Recently, two factors have been identified as important in the physiopathology of hemostasis and coagulation: the presence of clonal hematopoiesis of indetermined potential (CHIP) and the formation of neutrophil extracellular traps (NETs). In this study, these two factors will be studied in patients with repeated venous thrombosis or thrombosis occurring in unusual site.
It has recently been shown that some patients clonal have mutations at a low level in hematopoietic cells (this phenomenon is named clonal hematopoiesis of indetermined potential (CHIP)) and that the presence of a clonal hematopoiesis is associated with an increased cardiovascular risk. However, few data exist about the implication of CHIP in venous thrombosis. Neutrophils extracellular traps are involved in the activation of hemostasis and coagulation. Murine models have highlighted the crucial role of NETs in the physiopathology of venous thrombosis. In patients, studies have demonstrated that NETs markers were present in arteries lesions as coronary plaques. However, few studies have analyzed the NETosis in the setting of venous thrombosis. The study hypothesis is that patients with venous thrombosis may have an increased prevalence of CHIP and/or an increased NETosis formation, which may represent a predisposition for the occurrence of venous thrombosis. We also speculate that patients with CHIP may have an increased NETosis, due to the presence of activating clonal mutations in neutrophils. Patients included will be : younger than 50-years-old with repeated thrombosis or thrombosis of unusual sites (cerebral venous thrombosis, splanchnic thrombosis) with a negative etiological workup and notably the absence of constitutional or acquired venous thrombosis risk factors. In this population, we will analyze the prevalence of CHIP and the NETosis via the study of 4 different NETosis plasmatic markers.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
150
The procedure will consist of an additional blood sample for ETDA tube collection (NGS analysis) and citrate tube collection (NETose analysis)
CHU de Bordeaux, Service de Neurologie
Bordeaux, France
NOT_YET_RECRUITINGCHU de Bordeaux, Service Gastro-Entérologie
Bordeaux, France
NOT_YET_RECRUITINGCHU de Bordeaux, Service Hématologie Biologique
Bordeaux, France
RECRUITINGCHU de Bordeaux, Service Médecine Vasculaire
Bordeaux, France
RECRUITINGCHU de Bordeaux, Unité ambulatoire de Médecine Vasculaire
Bordeaux, France
RECRUITINGCHU de Lille, Service Hémostase Clinique
Lille, France
NOT_YET_RECRUITINGAPHM - Hôpital de la Timone, Service Hématologie
Marseille, France
NOT_YET_RECRUITINGPresence of clonal hematopoiesis
The existence of clonal hematopoiesis will be defined as the demonstration of at least one mutation in the blood cells of an apparently healthy subject (without obvious hematological pathology). DNA will be extracted from circulating leukocytes to search for mutations in a panel of 59 genes
Time frame: At baseline
Presence of one or more increased NETosis markers and/or a decreased NETosis-inhibiting marker (DNAse level) compared to a control population.
Analysis of the following markers: MPO-DNA complex, Histone 3-DNA complex, citrullinated histone 3, DNAse
Time frame: At baseline
Correlation (correlation coefficient values) between the presence of a CHIP and the formation of NETs
Correlation analysis will be performed between each NETosis marker and CHIP evaluation (presence or absence, number of mutations, variant allele frequency for each mutation)
Time frame: During final analysis
Allele frequency
Variant allele frequency of each detected mutation will be determined using NGS analysis
Time frame: At baseline
Number of clonal mutations
The number of clonal mutations for each patient will be determined using NGS analysis
Time frame: At baseline
C-reactive protein (CRP) level as a marker of inflammation
C-reactive protein concentration will be determined for each patient, as a marker of inflammation
Time frame: At baseline
Site(s) of thrombosis
Site(s) of thrombosis will be determined during examination of the patient
Time frame: At baseline
Number of thrombosis
The number of thrombosis will be determined during examination of the patient
Time frame: At baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.